Results 101 to 110 of about 2,980 (135)

A Systems Hypothesis of Lipopolysaccharide-Induced Vitamin Transport Suppression and Metabolic Reprogramming in Autism Spectrum Disorders: An Open Call for Validation and Therapeutic Translation. [PDF]

Metabolites
Dervishi A.
europepmc   +1 more source

2-Hydroxyglutarate in onco-pathway: a metabolic driver of proto-oncogene activation. [PDF]

Front Oncol
Thamim M, Dhabal D, Balamurali MM, Thirumoorthy K.   +3 more
europepmc   +1 more source

Metabolic reprogramming in bone metastasis of human cancers. [PDF]

Front Cell Dev Biol
Li T, Wang Z, Yang H, Kang Y.
europepmc   +1 more source

Transcriptome-constrained genome-scale metabolic modeling reveals central carbon and amino acid metabolic reprogramming underlying colistin-sulbactam synergy in <i>Acinetobacter baumannii</i>. [PDF]

Antimicrob Agents Chemother
Bian X, Zhu Y, Liu X, Li X, Li W, Zhao J, Li J, Zhang J.   +7 more
europepmc   +1 more source

Vitamin B₆ form produced by Lactobacillus induces metabolic disorder and suppresses multi-pathogenic bacteria. [PDF]

Commun Biol
Wu Y, Ling Z, Peng L, Wang X, He Y, Khan A, Salama ES, Kulshreshtha S, Liu P, Liu P, Li X.   +10 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Phosphoserine Aminotransferase 1: A Metabolic Enzyme Target of Cancers

Current Cancer Drug Targets, 2023
Abstract: Phosphoserine aminotransferase 1 (PSAT1) catalyzes 3-phosphohydroxylpyruvate and glutamate into 3-phosphoserine and α-ketoglutamate. It integrates metabolic pathways critical for cell proliferation, survival, migration and epigenetics, such as glycolysis, de novo serine synthesis, citric acid cycle and one-carbon metabolism.
Yuping Chen
exaly   +3 more sources

Downregulation of Phosphoserine aminotransferase 1 promotes tumorigenesis in Glioblastoma

The FASEB Journal, 2020
Glioblastoma (GBM) is a typical brain tumor with survival below ten percent at 5 years after diagnosis. The genetic alternation and histological features are integrated into the classification of gliomas for better clinical management of GBM.
Yung-chieh Chan, Shang-Pen Huang, Yu-Chan Chang, Michael Hsiao   +3 more
openaire   +1 more source

Abstract 1435: Investigation of phosphoserine aminotransferase 1: Its role in breast cancer progression

Cancer Research, 2018
Abstract Metastasis and endocrine resistance are two factors that complicate therapeutic intervention in breast cancer patients and lead to poorer overall survival. Metastasis is known to be responsible for 90% of cancer related deaths, and is especially prevalent in triple negative breast cancer (TNBC); while endocrine resistance can ...
Stephanie Metcalf, Traci Kruer, James Wittliff, Carolyn Klinge, Brian F. Clem   +4 more
openaire   +1 more source

Abstract 1163: Phosphoserine aminotransferase 1 (PSAT1) as a novel anti-tumor target in hepatocellular carcinoma

Cancer Research, 2015
Abstract With an estimated 700,000 new cases per year, hepatocellular carcinoma (HCC) represents the fifth commonest cancer and is the third leading cause of cancer death worldwide. Its 5-year survival rate after surgery is only 5-6%.
Zhaobing Ding, Kenneth Wee, Eung-Sam Kim, Animesh Samanta, Michael Steckel, Marian Raschke, Sendhil Velan, Young-Tae Chang, Andrea Haegebarth, Karl Ziegelbauer, Sylvia Gruenewald, Weiping Han   +11 more
openaire   +1 more source

Abstract P1-01-15: Investigation of phosphoserine aminotransferase 1 and its role in breast cancer progression

Cancer Research, 2018
Abstract Metastasis and endocrine resistance are two factors that complicate therapeutic intervention in breast cancer patients and lead to poorer overall survival. Metastasis is known to be responsible for 90% of cancer related deaths, and is especially prevalent in triple negative breast cancer (TNBC); while endocrine resistance can ...
S Metcalf, T Kruer, C Klinge, B Clem
openaire   +1 more source